ATF6 and prostate cancer: Previously, an accumulation of ATF6 in prostate cancer cells due to NFV-mediated inhibition of site-2 protease (S2P) enzyme was reported, which interrupted the regulated intramembrane proteolysis (RIP) of ATF6 in the Golgi apparatus for the release of the active soluble form [66].